TIGIT in cancer immunotherapy
Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cells’ survival and function. During the last decade, immunothera...
Saved in:
| Main Authors: | Joe-Marc Chauvin, Hassane M Zarour |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000957.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
by: Haozhe Cui, et al.
Published: (2024-11-01) -
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01) -
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
by: Friedrich Haag, et al.
Published: (2022-12-01) -
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
by: Shuai Chen, et al.
Published: (2020-10-01) -
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
by: Dean A Lee, et al.
Published: (2023-12-01)